A Phase 1, Fixed Sequence, Open-Label Study to Evaluate the Effect of Multiple Doses of Rabeprazole on the Pharmacokinetics of a Single Dose of Radiprodil in Healthy Adult Participants

Start Date26 Aug 2024

Sponsor / Collaborator

GRIN Therapeutics, Inc.

[+1]

NCT04923113

/ CompletedNot ApplicableIIT

Comparison of Different Helicobacter Pylori Detection Methods in Patients With Chronic Atrophic Gastritis

As we know，Helicobacter pylori is closely related to many gastrointestinal diseases such as chronic gastritis, peptic ulcer disease,gastric carcinoma and gastric mucosa-associated lymphoid tissue lymphoma，as well as extra-digestive diseases such as urticaria and chronic obstructive pulmonary diseases and so on.The diagnosis of H. pylori infection is based on invasive methods requiring endoscopy and biopsy(e.g. histology, culture, rapid urease test, PCR) or on non-invasive methods (e.g. serology, 13C urea breath test, stool antigen test).Histology has the highest specificity among the others,and also allows us to determine the underlying disease and perform antibiotic sensitivity testing.Serological tests are widely available and more appropriate for epidemiological studies, their main weakness for clinical use is low specificity.The 13C urea breath test is the most accurate method in patients irrespective of age.Stool antigen testing,as a promising method, is easy to perform, and its accuracy may be improved by the use of monoclonal antibodies recently proposed for capturing H. pylori antigen in stool specimen.Sensitivity and specificity, usefulness,and limitation of tests should be considered for selection of detection methods of H. pylori. Our objective is to review the current methods that are used for the detection of H. pylori infection among patients with chronic atrophic gastritis.Except that,patients with Hp positive will be further treated with 10-day minocycline-based quadruple therapy,to observe the efficacy and safety of minocycline-based regimen for H.pylori eradication as a first-line therapy.

Start Date28 Jun 2021

Sponsor / Collaborator

The Second Affiliated Hospital Zhejiang University

NCT04565574

/ CompletedPhase 1

An Open-Label, Single-Dose Study to Assess the Effect of Food Intake and Drug-Drug Interactions of E7090 When Co-administered With Rabeprazole (Gastric Acid-Reducing Agent), or Rifampin (Strong CYP3A Inducer) in Healthy Subjects

This study will have three parts: Part A, Part B, and Part C. The primary purpose of Part A is to evaluate the effect of food on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part B is to evaluate the effects of rabeprazole (a gastric acid-reducing agent) on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part C is to evaluate the effects of rifampin (a strong Cytochrome P450 3A [CYP3A] inducer) on pharmacokinetics (PK) of single oral doses of E7090 in healthy participants.

Start Date16 Oct 2020

Sponsor / Collaborator

Eisai Co., Ltd.

100 Clinical Results associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

100 Translational Medicine associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

100 Patents (Medical) associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

1,226

Literatures (Medical) associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

03 Feb 2026·Zhonghua yi xue za zhi

[Analysis of the efficacy and safety of magaldrate granules quadruple therapy in the treatment of Helicobacter pylori infection].

Article

Author: Meng, F D ; Zhang, S T ; Liu, J X ; Zou, D W ; Ding, X L ; Yao, C ; Wang, J B ; Zhu, Y M ; Tian, Z B ; Wang, X K ; Yang, G B ; Yuan, Y Z ; Zhang, G Y ; Ye, F ; Zheng, P Y ; Dong, X H ; Li, L ; Yang, L ; Jiang, X F ; Sun, J ; Huang, H ; Hu, F L ; Liu, S D ; Li, Y ; Xu, M H ; Zhang, G X ; Gao, W

Objective: To evaluate the efficacy and safety of a quadruple therapy consisting of magaldrate granules combined with rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori (Hp). Methods: The patients diagnosed with chronic gastritis and Hp positive via gastroscopy for the first time were prospectively collected from 11 centers in China from June 2021 to May 2024. The patients were divided into three groups according to random number table method: Group A (magaldrate granules quadruple therapy for 14 days), Group B (magaldrate granules quadruple therapy for 10 days and magaldrate granules for 18 days), and Control Group (bismuth quadruple therapy for 14 days). The patients were followed up 3 days after treatment, and 4 weeks after the end of treatment. The analysis data set was used for effectiveness analysis [the eradication rate of Hp was analyzed using the full analysis dataset (FAS) and the per-protocol dataset (PPS)], and non-inferiority evaluation was conductedusing (comparing the rate difference and 95%CI of the eradication rate of Hp. If the lower limit was greater than the preset -10%, the non-inferiority test standard was met). The occurrence of symptoms and adverse reactions were analyzed in each group. Results: A total of 557 patients were enrolled, with 227 males and 330 females, aged (46±12) years (18-65 years). The Hp eradication rates according to FAS were 84.6% (159/188) in Group A, 83.2% (153/184) in Group B, and 85.4% (158/185) in Control Group, respectively. A total of 527 cases were included in PPS analysis, and the Hp eradication rates were 88.8% (158/178), 88.8% (150/169),and 87.2% (157/180) in the three groups, respectively. In the FAS and PPS analyses, there was no significant difference in the Hp eradication rates between Group A and Control Group, or Group B and Control Group (all P>0.05). The rate differences and 95%CI were -0.83% (-8.08%-6.42%) and 1.54% (-5.19%-8.27%) between Group A and Control Group. The rate differences and 95%CI were -2.25% (-9.68%-5.17%) and 1.54% (-5.28%-8.35%) between Group B and Control Group. The lower limits of all confidence intervals exceeded the pre-specified non-inferiority margin of -10%, meeting the criteria for non-inferiority. All three groups of patients exhibited symptoms such as epigastric distension, belching, epigastric pain, and poor appetite. After 3 days of treatment, the relief rate from epigastric pain in Group A [85.9% (55/64)] and Group B [91.2% (52/57)] was higher than Control Group [70.2% (40/57)] (both P<0.05). Adverse reactions of varying severity, including dizziness, nausea, vomiting, abdominal pain, diarrhea, and rash, were reported in all three patient groups. No statistically significant differences were found in the incidence rates of these adverse events between Group A and Control Group, or Group B and Control Group (all P>0.05). Conclusion: The quadruple therapy combining magaldrate granules with rabeprazole, amoxicillin, and clarithromycin demonstrates good Hp eradication efficacy and high safety.

01 Feb 2026·JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Efficacy and safety of ten-day bismuth quadruple therapy for first-line anti-Helicobacter pylori infection in the elderly- A multicenter real-world report

Article

Author: Liang, Chih-Ming ; Tai, Wei-Chen ; Huang, Kuo-Hsuan ; Loke, Song-Seng ; Yao, Chih-Chien ; Chuah, Seng-Kee ; Wu, Deng-Chyang ; Tsay, Feng-Woey ; Hsu, Pin-I

BACKGROUND:

Aging may influence the effectiveness of Helicobacter pylori (H. pylori) eradication. The purpose of this study was to evaluate the efficacy and safety of 10-day bismuth quadruple therapy as a first-line treatment for H. pylori infection in elderly individuals.

METHODS:

We conducted a retrospective analysis of prospectively collected data from September 2018 to December 2021 in southern Taiwan. All patients received 10-day quadruple therapy consisting of rabeprazole 20 mg twice daily, bismuth subcitrate 120 mg four times daily, metronidazole 500 mg three times daily, and tetracycline 500 mg four times daily. Patients were categorized into two groups: an elderly group (aged ≥65) and a control group (aged <65).

RESULTS:

The study included 231 naive patients receiving 10-day quadruple therapy. The eradication rates in the elderly and control groups were 80.3 % (95 % confidence interval [CI]: 68.1 %-89.4 %) and 85.3 % (95 % CI: 79.1 %-90.3 %) (P = 0.364), respectively, in the intention-to-treat analysis. In the per-protocol analysis, eradication rates were 89.1 % (95 % CI: 77.8 %-95.9 %) for the elderly group and 94.8 % (95 % CI: 90.0 %-97.7 %) for the control group (P = 0.149). Adverse event rates were 34.5 % in the elderly group and 27.5 % in the control group (P = 0.322). Compliance was slightly lower in the elderly group than the control group (89.1 % vs. 95.4 %, P = 0.096).

CONCLUSIONS:

The efficacy of 10-day bismuth quadruple therapy as a first-line treatment for H. pylori was comparable between elderly and non-elderly cohorts, with similar levels of adverse effects.

01 Jan 2026·LANCET INFECTIOUS DISEASES

Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial

Article

Author: Liao, Aijun ; Zheng, Pengyuan ; Zuo, Xiuli ; Li, Fangfang ; Yang, Shaoqi ; Gao, Xiang ; Zeng, Zhirong ; Chen, Lei ; Zou, Chuanxin ; Ma, Zhenkun ; Xu, Min ; Gu, Yongsong ; Song, Zhiqiang ; Lan, Cheng ; Gao, Hong ; Zheng, Jianwei ; Zhen, Yanbo ; Zeng, Xin ; Wang, Xuehong ; Chen, Huixin ; Du, Qin ; Chen, Zhengyi ; Li, Xing ; Geng, Guozhu ; Xu, Meihua ; Chen, Jing ; Zhou, Liya ; Zhang, Hong ; Xie, Jun ; Chen, Tao ; Xu, Jianguang ; Liu, Gaifang ; Wang, Weihong ; Zhang, Xiaojie ; Zhu, Yin ; Tang, Tongyu ; Fan, Huizhen ; Wang, Hong ; Feng, Huang ; Wang, Qizhi ; Liu, Chengxia ; Tan, Shiyun ; Xu, Hongzhi ; Zhang, Qing

BACKGROUND:

Rifasutenizol (TNP-2198) is a new molecular entity with a synergistic dual mechanism of action under clinical development for the treatment of Helicobacter pylori infection. We aimed to evaluate the efficacy and safety of a rifasutenizol-based triple therapy (RTT) versus bismuth plus clarithromycin-based triple therapy (BCTT) for the treatment of H pylori infection in treatment-naive patients.

METHODS:

EVEREST-HP was a phase 3, randomised, triple-dummy, double-blind, active-controlled, non-inferiority trial with adaptive design for sample size re-estimation conducted at 40 research hospitals in China. Treatment-naive patients aged 18-65 years, with a positive [¹³C]urea breath test ([¹³C]UBT), further confirmed by gastric biopsy and histological examination, were randomly assigned (1:1) to receive RTT (rifasutenizol 400 mg oral capsules, amoxicillin 1 g oral capsules, and rabeprazole 20 mg enteric-coated tables) or BCTT (bismuth potassium citrate 240 mg oral tablets, clarithromycin 500 mg oral tablets, amoxicillin 1 g oral capsules, and rabeprazole 20 mg enteric-coated tablets), all twice a day for 14 days. Randomisation was done centrally by a secure interactive web response system using block sizes of two or four and stratified by study site. RTT was compared against BCTT using a triple-dummy approach to ensure masking. The primary endpoint was H pylori eradication rate based on [¹³C]UBT 4-6 weeks after the end of treatment in the modified intention-to-treat population, which included all participants who received at least one dose of the study drugs. The eradication rates of RTT and BCTT were compared using a one-sided α value of 0·025 and a non-inferiority margin of -10%. Safety endpoints included investigator assessed treatment-emergent adverse events, the severity and relationship with study drugs, findings from physical examinations, vital signs, laboratory tests, and electrocardiogram. An interim analysis was conducted by an independent data monitoring committee after 50% (350) of patients completed the last [¹³C]UBT. The trial is registered with ClinicalTrials.gov, NCT05857163.

FINDINGS:

Between May 18, 2023, and Nov 10, 2023, 1267 patients were screened and 700 patients were randomly assigned to receive either RTT (n=353) or BCTT (n=347). 261 (37%) patients were men and 439 (63%) were women. 351 patients in the RTT group and 346 in the BCTT group took at least one dose of the study drugs and were included in the modified intention-to-treat group and the safety set. H pylori was successfully cultured from 579 (83%) of 697 patients. 236 (41%) of 579 patients had H pylori infection resistant to clarithromycin, 395 (68%) to metronidazole, 203 (35%) to levofloxacin, and 47 (8%) to amoxicillin. All H pylori clinical isolates were susceptible to rifasutenizol. In the modified intention-to-treat analysis, the H pylori eradication rate in the RTT group was non-inferior to that in the BCTT group (92·0% [95% CI 88·7 to 94·6; 323 of 351] vs 87·9% [83·9 to 91·1; 304 of 346]; absolute difference 4·2% [95% CI -0·3 to 8·8]). 131 (37%) of 351 patients in the RTT group and 184 (53%) of 346 in the BCTT group had treatment-emergent adverse events. Treatment-emergent adverse events occurring in more than 5% of patients in the RTT group were diarrhoea (in 24 [7%] patients), nausea (22 [6%]), and dizziness (21 [6%]), and in more than 5% of patients in the BCTT group were taste perversion (125 [36%]), nausea (21 [6%]), and diarrhoea (19 [5%]) Most of the treatment-emergent adverse events were mild or moderate in severity. No serious adverse event related to study drugs was reported.

INTERPRETATION:

As the first novel antimicrobial agent specifically developed for H pylori infection, rifasutenizol represents a promising addition to the existing options for tackling antimicrobial resistance, and RTT represents a promising first-line treatment option for H pylori infection.

FUNDING:

TenNor Therapeutics.

TRANSLATION:

For the Chinese translation of the abstract see Supplementary Materials section.

News (Medical) associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

02 Jun 2025

·www.eisai.com

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan

For Print June 2, 2025 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the launch of “Pariet® S” (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn and stomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan. 1 "Pariet S" is the first proton pump inhibitor (PPI 2) to receive manufacturing and marketing approval as an over the counter (OTC) medicine in Japan. Rabeprazole sodium, in an amount equivalent to that used in the prescription product 3, works directly on the proton pumps that produce stomach acid, effectively alleviating severe heartburn caused by gastric acid reflux and stomach pain due to excessive acid secretion. The medicine comes in small, easy-to-swallow tablets, with a once-daily dosage providing 24-hour relief. Rabeprazole sodium, the active ingredient in “Pariet S”, is a PPI developed at Eisai’s Tsukuba Research Laboratories. The medicine was first launched in Japan in 1997 as a prescription pharmaceutical under the brand name “Pariet” and has since been approved more than 100 countries worldwide. It is widely prescribed to people struggling with acid-related disorders. In recent years, there is a tendency for increased stomach acid secretion due to disrupted eating habits, stress, and a decline in the infection rate of Helicobacter pylori. Moreover, the number of individuals experiencing gastric acid reflux has grown, driven by age-related weakening of the lower esophageal sphincter. Eisai will introduce “Pariet S” as a new treatment option in the OTC gastric medication market, aiming to alleviate sever heartburn and discomfort caused by gastric acid related conditions, and strongly support people in the daily living domain who wish for a comfortable and secure daily life. For further details, please refer to the product’s website for details about "Pariet S" (Japanese only) https://www.eisai.jp/products/pariet/pariets 1 "Pariet S" is classified as a drug that requires a pharmacist’s guidance at the time of sale 2 Proton Pump Inhibitor suppresses gastric acid secretion by inhibiting the “proton pump” which is the final step in the secretion process. 3 Contains rabeprazole10mg per tablet Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120 [Notes to editors] Product Outline 1. Product Name: “Pariet® S” (RX-to-OTC switch, pharmaceutical requiring guidance) 2. Ingredients: Per daily dose of one tablet: rabeprazole sodium 10mg Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate 3. Indications and Usage: Stomach pain, heartburn, and bloating (This medicine contains a proton pump inhibitor which suppresses stomach acid secretion.) 4. Dosage and Administration: Adults (15 years and older): 1 tablet once daily. Do not use this medicine consecutively for more than two weeks. 5. Packaging and Recommended Retail Price (excluding tax): Packaging: 6 tablets, Recommended retail price: 1,480 yen 6. Manufactured and marketed by: Eisai Co., Ltd. Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate Full text

Drug Approval

29 Mar 2025

·pharma.economictimes.indiatimes.com

103 drug samples fail CDSCO quality test, popular brand Telma H flagged as spurious

New Delhi: During its monthly quality review, the drug regulatory body identified 103 drug samples as ‘Not of Standard Quality’ ( NSQ ) and flagged a sample of the popular brand Telma H as ‘spurious.’ Of the 103 drug samples that failed to meet the quality standards, 47 were identified by central drug laboratories, while the remaining 56 were identified by state drug laboratories in the country. The drug sample that has been labeled as “spurious” is Telma H (Telmisartan 40mg & Hydrochlorothiazide 12.5mg), a popular brand prescribed for high blood pressure patients. As per the Union Health Ministry note, the sample was picked from West Bengal. As per the February drug alert issued by the Central Drugs Standard Control Organisation (CDSCO), the sample was manufactured in 2022 and the reason for the drug test failure as notified in the alert suggests that the sample “does not conform to I.P.” (Indian Pharmacopoeia). The branded generic drug is marketed by Glenmark and, as per an analysis from market research firm Pharmarack, it features among the top 50 brands in the country, with a moving annual total (MAT) value of around ₹447 crore. Regarding the identified spurious drug sample, the Health Ministry, in its quality review announcement, stated that the sample is “made by an unauthorized manufacturer using a brand name owned by another company. The matter is under investigation and action.” CDSCO, in its drug quality alert, has remarked that the product is purported to be spurious; however, the same is subject to the outcome of the investigation. The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. The 47 NSQ samples identified by the central laboratories include Rabeprazole Tablets manufactured by Martin & Brown BioSciences Pvt. Ltd.; Paracetamol & Diclofenac Sodium Tablets manufactured by I.G. PHARMA LTD.; and Telmisartan Tablets IP by Orison Pharma International, among 44 others. Whereas, the list from state laboratories comprises Calcium & Vitamin D3 Tablets manufactured by Affy Parenterals Vill.; Phenytoin Tablets by Jackson Laboratories; and Cloprostenol Injection by Monatt Biotech, including 53 others. According to CDSCO, a drug shall be deemed spurious if it is manufactured under a name belonging to another drug; if it is an imitation of, or a substitute for, another drug; if it resembles another drug in a manner likely to deceive; or if it bears upon its label or container the name of another drug, among other provisions defined under Section 17-B of the Drugs and Cosmetics Act, 1940. Whereas drugs that fail to meet quality standards or specifications are notified as NSQ, a term defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. By Abhijeet Singh ,

13 Jun 2024

·www.pharmaindustrial-india.com

Akums Launches Rabeprazole + Levosulpiride SR Capsules

Akums Drugs & Pharmaceuticals Ltd. announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders. GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer. “Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects,” the company said in a statement. Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology, it claimed. “We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients’ overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience,” Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd. said in a statement. Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.

Drug Approval

100 Deals associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Rabeprazole Sodium/Metronidazole/Amoxicillin	J01CR02	DB01129

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gastritis	Japan	Eisai Co., Ltd.	21 Nov 2013
Duodenal Ulcer	Japan	Eisai Co., Ltd.	15 Aug 2013
Helicobacter pylori infection	Japan	Eisai Co., Ltd.	15 Aug 2013
Purpura, Thrombocytopenic, Idiopathic	Japan	Eisai Co., Ltd.	15 Aug 2013
Stomach Ulcer	Japan	Eisai Co., Ltd.	15 Aug 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Erosive gastro-esophageal reflux disease	Phase 3	Germany	Eisai Manufacturing Ltd.	26 Jun 2008
Asthma	Phase 3	United States	Eisai, Inc.	01 Sep 2002
Gastroesophageal Reflux	Phase 3	United States	Eisai, Inc.	01 Sep 2002
Dyspepsia	Phase 2	Japan	Eisai Co., Ltd.	01 Apr 2010
Nasopharyngeal Diseases	Phase 2	United States	Eisai, Inc.	01 Jun 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2019	Not Applicable	Helicobacter pylori infection	-	Quadruple therapy 10 days (QT-10)	ruaquvjkiw(mdznvkgwzg) = The overall incidence of AEs was also significantly lower in the OST-14 group, compared to QT-10 and QT-14 groups (21.2%, 37.2% and 41.6% respectively, p=0.02 ) gqqiuvltel (frrcshnjdk )	Positive	01 Oct 2019
NCT02135107 (EXTEND, CTgov)	Phase 3	Gastroesophageal Reflux	517	Rabeprazole (Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily)	akeohwqspo = bzfyjmgugc rslidnfmoy (mbvicuilxf, scwgpcueea - vyupjtngau) View more	-	19 Nov 2018
				Rabeprazole (Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily)	akeohwqspo = qprxocjmgj rslidnfmoy (mbvicuilxf, uygcnamfvb - yfppkuqwdr) View more
NCT02135107 (EXTEND, Pubmed \| J Gastroenterol)	Phase 3	Esophagitis, Peptic Maintenance	517	Rabeprazole 10 mg q.d.	kielmmoqxx(vlrdntgdhq) = ewdrymvqks qlcdchwfoq (vrqqyiciqn )	-	01 Jul 2018
				Rabeprazole 10 mg b.i.d.	kielmmoqxx(vlrdntgdhq) = rbbcstbvkj qlcdchwfoq (vrqqyiciqn )
NCT01398410 (CTgov)	Phase 2/3	Stomach Ulcer	405	Rabeprazole (Rabeprazole 5 mg)	riuxshgovl = birpgsbaxh ycbbonxvjm (phzapreayg, hhuvctvotx - bzolripthh) View more	-	16 Nov 2015
				Rabeprazole (Rabeprazole 10 mg)	riuxshgovl = sctfecrixa ycbbonxvjm (phzapreayg, hjfuhxtjqd - gzhrreqmxo) View more
NCT01922765 (Pubmed \| World J Gastroenterol)	Phase 4	Helicobacter pylori infection	680	Clarithromycin-based triple therapy	itpreiupza(agxregukeh) = dqkvfgodes ssscifpare (vyrsnebdow )	-	01 Jan 2015
				Metronidazole-based triple therapy	itpreiupza(agxregukeh) = ixsbeudwpa ssscifpare (vyrsnebdow )
NCT00539240 (CTgov)	Phase 2/3	Pain \| Gastroesophageal Reflux	236	placebo+Rabeprazole (Arm 1)	maxjcnnais(fddvgjmwjj) = uadcfdrweu myleuuacoy (rltjesxzhq, 0.9) View more	-	18 Aug 2014
				placebo+Rabeprazole (Arm 2)	maxjcnnais(fddvgjmwjj) = gpcfookzmb myleuuacoy (rltjesxzhq, 2.2) View more
NCT01089543 (SAMURAI \| E3810-J081-204, CTgov)	Phase 2	Dyspepsia	338	Rabeprazole (Rabeprazole 10 mg)	nrzgaqxsyu = brayvbvftm wftywllupo (iktiebpnby, nxwndxctut - jichiqvzsa) View more	-	19 Nov 2013
				Rabeprazole (Rabeprazole 20 mg)	nrzgaqxsyu = mutoakgiic wftywllupo (iktiebpnby, agjqkhviot - abyppwbhav) View more
NCT01089543 (SAMURAI, Pubmed \| Aliment Pharmacol Ther)	Phase 2	Dyspepsia	392	Rabeprazole 20 mg	uefgxoemzy(gtmceqosvx) = rlqucfeqri dnyiekyqzj (qmlloawtwy )	Positive	01 Oct 2013
				Placebo	uefgxoemzy(gtmceqosvx) = jikkdfupou dnyiekyqzj (qmlloawtwy )
NCT00787891 (CTgov)	Phase 3	Gastroesophageal Reflux	127	Rabeprazole Sodium (Rabeprazole Sodium 0.5 mg/kg)	hribvxvjlp = vkkfrpikje sdjxotclvn (wspblxjcbu, icgxnubjuw - rjhsdrzclg) View more	-	11 Oct 2012
				Rabeprazole Sodium (Rabeprazole Sodium 1.0 mg/kg)	hribvxvjlp = lccfflcpkl sdjxotclvn (wspblxjcbu, orrzioytrw - swntoiqkbb) View more
NCT00165841 (CTgov)	Phase 2	Gastroesophageal Reflux	200	Rabeprazole 20 mg (Rabeprazole 20 mg)	hubwmttncu(qkjsqbdusc) = ouyvjqbhec imigdikryt (xxtcbboinp, 14.39) View more	-	03 Dec 2009
				Rabeprazole 20 mg (Placebo)	hubwmttncu(qkjsqbdusc) = pjqfqgrgcl imigdikryt (xxtcbboinp, 29.93) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis